Next Article in Journal
KCa3.1 Channels Confer Radioresistance to Breast Cancer Cells
Previous Article in Journal
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets
Review

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

1
Department of Radiation Oncology, Brescia University, 25123 Brescia, Italy
2
Department of Radiation Oncology, ASST Spedali Civili of Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy
3
Radiation Oncology Service, ASST Valcamonica, 25040 Esine, Italy
4
Department of Molecular and Translational Medicine, Unit of Biotechnology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(9), 1284; https://doi.org/10.3390/cancers11091284
Received: 29 July 2019 / Revised: 27 August 2019 / Accepted: 28 August 2019 / Published: 31 August 2019
Anticancer treatment efficacy is limited by the development of refractory tumor cells characterized by increased expression and activity of mechanisms promoting survival, proliferation, and metastatic spread. The present review summarizes the current literature regarding the use of the anthelmintic mebendazole (MBZ) as a repurposed drug in oncology with a focus on cells resistant to approved therapies, including so called “cancer stem cells”. Mebendazole meets many of the characteristics desirable for a repurposed drug: good and proven toxicity profile, pharmacokinetics allowing to reach therapeutic concentrations at disease site, ease of administration and low price. Several in vitro studies suggest that MBZ inhibits a wide range of factors involved in tumor progression such as tubulin polymerization, angiogenesis, pro-survival pathways, matrix metalloproteinases, and multi-drug resistance protein transporters. Mebendazole not only exhibits direct cytotoxic activity, but also synergizes with ionizing radiations and different chemotherapeutic agents and stimulates antitumoral immune response. In vivo, MBZ treatment as a single agent or in combination with chemotherapy led to the reduction or complete arrest of tumor growth, marked decrease of metastatic spread, and improvement of survival. Further investigations are warranted to confirm the clinical anti-neoplastic activity of MBZ and its safety in combination with other drugs in a clinical setting. View Full-Text
Keywords: chemoresistance; radioresistance; mebendazole; repurposing; cancer stem cells; cancer; CSC; anticancer; stemness chemoresistance; radioresistance; mebendazole; repurposing; cancer stem cells; cancer; CSC; anticancer; stemness
Show Figures

Figure 1

MDPI and ACS Style

Guerini, A.E.; Triggiani, L.; Maddalo, M.; Bonù, M.L.; Frassine, F.; Baiguini, A.; Alghisi, A.; Tomasini, D.; Borghetti, P.; Pasinetti, N.; Bresciani, R.; Magrini, S.M.; Buglione, M. Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers 2019, 11, 1284. https://doi.org/10.3390/cancers11091284

AMA Style

Guerini AE, Triggiani L, Maddalo M, Bonù ML, Frassine F, Baiguini A, Alghisi A, Tomasini D, Borghetti P, Pasinetti N, Bresciani R, Magrini SM, Buglione M. Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers. 2019; 11(9):1284. https://doi.org/10.3390/cancers11091284

Chicago/Turabian Style

Guerini, Andrea E., Luca Triggiani, Marta Maddalo, Marco L. Bonù, Francesco Frassine, Anna Baiguini, Alessandro Alghisi, Davide Tomasini, Paolo Borghetti, Nadia Pasinetti, Roberto Bresciani, Stefano M. Magrini, and Michela Buglione. 2019. "Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature" Cancers 11, no. 9: 1284. https://doi.org/10.3390/cancers11091284

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop